Tag: Cancer Drugs

AstraZeneca and Merck’s LYNPARZA® Phase 3 PAOLA-1 Trial Presented

astrazeneca
AstraZeneca and Merck, known as MSD outside the United States and Canada, announced detailed positive results from the Phase 3 PAOLA-1 trial showing LYNPARZA added to bevacizumab demonstrated a statis...

GSK Announced Results from PRIMA Study of Zejula

gsk
GlaxoSmithKline plc announced results from PRIMA (ENGOT-OV26/GOG-3012), the Phase 3 randomised, double-blind, placebo-controlled study of Zejula (niraparib) as a maintenance therapy in women with firs...

Amgen Announced Positive Results from Two Clinical Trials Phase 3 BLINCYTO®

Amgen announced that the results of a prespecified interim analysis of an open-label, randomized, controlled global multicenter Phase 3 trial (20120215) showed that the primary endpoint of event-free ...

European Commission Granted Marketing Authorization for Bayer Vitrakvi®

Bayer
Bayer announced that the European Commission has granted marketing authorization in the European Union (EU) for the precision oncology treatment Vitrakvi® (larotrectinib). The drug is indicated for...

Ipsen Registered New Anticancer Drug in Russia

Ipsen announced the registration of a new anticancer drug in Russia, cabosantinib. The drug is intended for the treatment of advanced renal cell carcinoma (RCC) in adult patients with intermediate or ...

FDA Approved ERLEADA® for Metastatic Castration-Sensitive Prostate Cancer Treatment

The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved ERLEADA® (apalutamide) for the treatment of patients with metastat...

FDA Approved Merck’s Lenvima Under New Project Orbis

The U.S. Food and Drug Administration is announcing Project Orbis, an initiative of the FDA Oncology Center of Excellence (OCE). Project Orbis provides a framework for concurrent submission and review...

FDA Granted Priority Review for Enfortumab Vedotin BLA for Urothelial Cancer Treatment

astellas
Seattle Genetics, Inc. and Astellas Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for the investigational agent enfortumab...

FDA Warned that Three Breast Cancer Drugs May Cause Severe Inflammation of Lungs

cancer treatment
The US Food and Drug Administration (FDA) warned that breast cancer drugs, Ibrance (palbociclib) from Pfizer, Novartis' Kisqali (ribociclib) and Lilly's Verzenio (abemaciclib) may cause rare but sever...

Teva and FSUE “Moscow Endocrine Plant” to Introduce Trizenox on Russian Market

On September 16, 2019, as part of the IV annual BIOTECHMED Biotechnology Forum, Teva and FSUE “Moscow Endocrine Plant” signed a Memorandum of Intent to implement actions aimed at introducing the Trize...

I-Mab Biopharma and Junshi Biosciences Announce Collaboration Agreement

I-Mab Biopharma (I-Mab), a China and U.S.-based clinical-stage biopharmaceutical company exclusively focused on the discovery and development of potential first-in-class and best-in-class biologics in...

Russian Researchers to Develop AIDS Treatment

Researchers from South Ural State University and the N.D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences are studying polysulphur-nitrogen heterocycles – organic compounds which ...

WHO Urged Countries to Eliminate Cervical Cancer by 2030

who
World Health Organization urged countries in its South-East Asia Region to accelerate efforts to eliminate cervical cancer by 2030. “Countries need to expand vaccination, screening, detection and tre...

EC Approved LONSURF® as Monotherapy for Treatment of Metastatic Gastric Cancer

Servier and its partner Taiho Pharmaceutical Co., Ltd announced that the European Commission (EC) has approved the use of LONSURF® (trifluridine/tipiracil) as monotherapy for the treatment of adult pa...

EU Approved Roche’s Tecentric plus Chemotherapy for Treatment of ES-SCLC

Roche announced that the European Commission has approved and granted marketing authorisation for Tecentriq® (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) for the initial...

Novartis Announced Positive Results for Ofatumumab Clinical Trials

Novartis, a global leader in neuroscience, announced positive results for ofatumumab (OMB157) from the Phase III ASCLEPIOS I and II studies. In both head-to-head studies, ofatumumab demonstrated su...